Suppr超能文献

替代强化物增强了阿片类拮抗剂而非激动剂对灵长类动物选择服用羟考酮的影响。

Alternative Reinforcers Enhance the Effects of Opioid Antagonists, but Not Agonists, on Oxycodone Choice Self-Administration in Nonhuman Primates.

机构信息

Behavioral Neuroimaging Laboratory, McLean Hospital, Belmont, Massachusetts (F.B.d.M., S.J.K.) and Department of Psychiatry, Harvard Medical School, Boston, Massachusetts (F.B.d.M., S.J.K.).

Behavioral Neuroimaging Laboratory, McLean Hospital, Belmont, Massachusetts (F.B.d.M., S.J.K.) and Department of Psychiatry, Harvard Medical School, Boston, Massachusetts (F.B.d.M., S.J.K.)

出版信息

J Pharmacol Exp Ther. 2024 Oct 18;391(2):301-307. doi: 10.1124/jpet.123.001911.

Abstract

Clinical reports suggest that the most effective strategies for managing opioid use disorder comprise a comprehensive treatment program of both pharmacological and nonpharmacological approaches. However, the conditions under which these combinations are most effective are not well characterized. This study examined whether the presence of an alternative reinforcer could alter the efficacy of Food and Drug Administration-approved opioid antagonist or agonist medications, as well as the nonopioid flumazenil, in decreasing oxycodone choice self-administration in nonhuman primates. Adult squirrel monkeys ( = 7; four females) responded under concurrent second-order fixed-ratio (FR)-3(FR5:S);TO45s schedules of reinforcement for intravenous oxycodone (0.1 mg/kg) or saline on one lever and 30% sweetened condensed milk or water on the other. Doses of naltrexone (0.00032-1.0 mg/kg), nalbuphine (0.32-10 mg/kg), buprenorphine (0.0032-0.032 mg/kg), methadone (0.32-1.0 mg/kg), or flumazenil (1-3.2 mg/kg) were administered intramuscularly prior to oxycodone self-administration sessions that occurred with either milk or water as the alternative. Naltrexone, a -opioid receptor antagonist, was >30-fold more potent when milk was available compared with water and abolished oxycodone intake (injections/session) while concomitantly increasing milk deliveries at the highest dose tested. Pretreatment with the low-efficacy -agonist nalbuphine was most effective in the presence of milk compared with water, decreasing oxycodone preference to <50% of control values. The higher efficacy -agonists, methadone and buprenorphine, and the benzodiazepine antagonist flumazenil did not appreciably alter the reinforcing potency of oxycodone under either condition. These results suggest that antagonist medications used in combination with alternative reinforcers may be an effective strategy to curtail opioid abuse-related behaviors. SIGNIFICANCE STATEMENT: Clinical treatment programs for opioid use disorder use a combination of pharmacological and nonpharmacological approaches. However, the conditions under which these combinations are most effective have not been fully characterized. This study examined whether the effectiveness of -opioid medications to decrease oxycodone self-administration is altered in the presence of an alternative reinforcer. The results suggest that alternative reinforcers enhance the effects of antagonist or low-efficacy partial agonists, suggesting they may be a more effective strategy to curtail opioid use.

摘要

临床报告表明,管理阿片类药物使用障碍最有效的策略包括药物和非药物治疗方案的综合治疗计划。然而,这些组合最有效的条件尚未得到很好的描述。本研究考察了替代强化物的存在是否会改变 FDA 批准的阿片类拮抗剂或激动剂药物以及非阿片类药物氟马西尼减少非人类灵长类动物氧可酮选择自我给药的效果。成年松鼠猴(n=7;4 只雌性)在静脉注射 0.1mg/kg 氧可酮或生理盐水(一个杠杆)和 30%甜炼乳或水(另一个杠杆)的同时,接受二阶固定比率(FR)-3(FR5:S);TO45s 强化方案的强化。在存在牛奶或水作为替代物的情况下,肌肉内给予纳曲酮(0.00032-1.0mg/kg)、纳布啡(0.32-10mg/kg)、丁丙诺啡(0.0032-0.032mg/kg)、美沙酮(0.32-1.0mg/kg)或氟马西尼(1-3.2mg/kg)。在牛奶或水存在的情况下,-阿片受体拮抗剂纳曲酮的效力比水高 30 多倍,在最高剂量下,纳曲酮完全消除了氧可酮的摄入(注射/疗程),同时增加了牛奶的输送量。与水相比,低效能-激动剂纳布啡在存在牛奶时的预处理最有效,将氧可酮的偏好降低到对照值的<50%以下。较高效能的-激动剂美沙酮和丁丙诺啡以及苯二氮䓬拮抗剂氟马西尼在两种情况下均未明显改变氧可酮的强化效力。这些结果表明,与替代强化物联合使用的拮抗剂药物可能是遏制阿片类药物滥用相关行为的有效策略。

意义声明

阿片类药物使用障碍的临床治疗方案结合了药物和非药物方法。然而,这些组合最有效的条件尚未得到充分描述。本研究检查了在存在替代强化物的情况下,-阿片类药物药物减少氧可酮自我给药的效果是否会改变。结果表明,替代强化物增强了拮抗剂或低效能部分激动剂的效果,这表明它们可能是遏制阿片类药物使用的更有效策略。

相似文献

4
Opioids for cancer pain - an overview of Cochrane reviews.用于癌症疼痛的阿片类药物——Cochrane系统评价综述
Cochrane Database Syst Rev. 2017 Jul 6;7(7):CD012592. doi: 10.1002/14651858.CD012592.pub2.
7
Opioid antagonists with minimal sedation for opioid withdrawal.用于阿片类药物戒断且镇静作用极小的阿片类拮抗剂。
Cochrane Database Syst Rev. 2017 May 29;5(5):CD002021. doi: 10.1002/14651858.CD002021.pub4.
8
Buprenorphine for managing opioid withdrawal.丁丙诺啡用于管理阿片类药物戒断。
Cochrane Database Syst Rev. 2017 Feb 21;2(2):CD002025. doi: 10.1002/14651858.CD002025.pub5.
9
Oxycodone for cancer-related pain.羟考酮治疗癌性疼痛。
Cochrane Database Syst Rev. 2022 Jun 9;6(6):CD003870. doi: 10.1002/14651858.CD003870.pub7.

本文引用的文献

1
Motivational interviewing for substance use reduction.动机性访谈减少物质使用。
Cochrane Database Syst Rev. 2023 Dec 12;12(12):CD008063. doi: 10.1002/14651858.CD008063.pub3.
5
Economic choice between remifentanil and food in squirrel monkeys.松鼠猴在瑞芬太尼和食物之间的经济选择。
Neuropsychopharmacology. 2022 Jun;47(7):1398-1404. doi: 10.1038/s41386-021-00996-6. Epub 2021 Apr 8.
10
Medications for opioid use disorder: bridging the gap in care.用于阿片类物质使用障碍的药物:弥合治疗差距。
Lancet. 2018 Jan 27;391(10118):285-287. doi: 10.1016/S0140-6736(17)32893-3. Epub 2017 Nov 14.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验